Celldex Therapeutics, Inc.

NASDAQ:CLDX

Biotechnology

Healthcare
$27.55 +0.47%

+$0.16 today

Market cap
$2.16B
Beta
0.93
P/E (TTM)
-7.8
EPS (TTM)
-$4.26
52W Low $19.52High $35.79

Volume 0.68M

Average 0.94M

CLDX Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Celldex Therapeutics, Inc.NASDAQ: CLDX

Weighted Avg Shares · Q3 FY2026 · quarter ended Sep 2026

Weighted avg shares growth accelerates

Q3 FY2026 weighted avg shares of 78.53M shares rose 18.2% year over year, ahead of the +9.0% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.9% from the prior quarter. Over 3 fiscal years it compounded at +12.4% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +18.2% holds above the trailing-twelve-month pace of +9.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
78.53M+0.9% QoQ
Last fiscal yearDec 2025
66.5M+3.3% YoY
LTMSep 2026
72.36M+9.0% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+18.2%——
1 year+3.3%——
3-year CAGR+12.4%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
66.5M USD
Year-over-year change
+3.3%
4-year CAGR
+11.6%

Weighted Avg Shares vs competitors

How CLDX compares with its peers on the latest reported figures

  • CLDX's LTM Sep 2026 weighted avg shares of 72.36M shares is the 7th highest of the 10 companies compared; the peer median is 93.98M shares.
  • Its year-over-year change of +9.0% is the 6th highest of 9, against a peer median of +18.9%.
  • Over three fiscal years its annual growth of +12.4% compares with a peer median of +14.3%.
CLDX Competitors Peer median
Weighted Avg Shares for CLDX and competitors
Company Period LTM YoY 3-year CAGR
CMPXCompass Therapeutics, Inc.LTM Mar 2026161.95M +17.8%+14.5%
RCUSArcus Biosciences, Inc.LTM Jun 2026116.35M +20.1%+14.3%
NRIXNurix Therapeutics, Inc.LTM Aug 2026106.95M +29.6%+21.3%
IMNMImmunome, Inc.LTM Sep 2026106.83M +34.8%+93.1%
CGENCompugen Ltd.LTM Mar 202693.98M +4.2%+2.6%
XNCRXencor, Inc.LTM Jun 202674.94M +5.1%+7.6%
CLDXCelldex Therapeutics, Inc.LTM Sep 202672.36M +9.0%+12.4%
MGNXMacroGenics, Inc.LTM Mar 202663.24M +0.8%+0.9%
ADAGAdagene Inc.LTM Jun 202435.12M —+2.9%
AGENAgenus Inc.LTM Mar 202633.32M +48.8%+28.3%
VRXAVeraxa Biotech Holding AG—— ——
Peer median (excluding CLDX) 93.98M+18.9%+14.3%

Competitors are the stored peer set for CLDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.65M2.36M6.88M7.02M1.5M
Cost of Revenue53.31M82.26M118.01M163.55M0
Gross Profit(48.66M)(79.9M)(111.13M)(156.53M)1.5M
Gross Margin-1046.2%-3389.9%-1614.5%-2229.8%100.0%
Research & Development56.81M82.26M118.01M163.55M245.1M
Selling, General & Admin20.49M27.2M30.91M38.55M43.8M
Operating Expenses22.58M35.33M43.41M38.55M288.9M
Depreciation & Amortization3.07M2.9M3.01M3.18M3.38M
EBITDA(66.08M)(104.2M)(139.03M)(154.69M)(255.42M)
EBITDA Margin-1420.8%-4420.9%-2020.0%-2203.5%-17028.0%
Operating Income(71.24M)(115.23M)(154.54M)(195.08M)(287.4M)
Operating Margin-1531.8%-4889.0%-2245.3%-2778.9%-19160.0%
Interest Income505K2.91M13.11M37.22M28.61M
Interest Expense00000
Other Income / Expenses505K2.91M13.11M37.22M28.6M
Income Before Tax(70.74M)(112.33M)(141.43M)(157.86M)(258.8M)
Pre-Tax Margin-1520.9%-4765.6%-2054.8%-2248.8%-17253.3%
Income Tax Expense(227K)0000
Net Income(70.51M)(112.33M)(141.43M)(157.86M)(258.8M)
Net Margin-1516.0%-4765.6%-2054.8%-2248.8%-17253.3%
EPS (Basic)(1.64)(2.40)(2.92)(2.45)(3.90)
EPS (Diluted)(1.64)(2.40)(2.92)(2.45)(3.90)
Weighted Avg Shares42.87M46.89M48.45M64.4M66.5M
Weighted Avg Shares (Diluted)42.87M46.89M48.45M64.4M66.5M

Celldex Therapeutics, Inc.

NASDAQ:CLDX

Intrinsic Alpha fair value

Locked

Current Price

$27.55

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.